Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > Financing announced. Shorts coming

<< Previous

Bullboard Posts

Next >>

Comment by Motherlode5155on Oct 14, 2018 10:40pm

36 Views

Post# 28799092

RE:Financing announced. Shorts coming

I think it’s standard practice to get 10-15% discount off last trade price for major investment. Hopefully this infusion of cash will speed up the greenhouse construction and get production up to full speed.

<< Previous

Bullboard Posts

Next >>

Oil industry trailblazer Sara Akbar discusses her vision for Sonoro